MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big pharma ...
The question of tariffs is not new. During President Donald Trump’s first term, the U.S. implemented significant tariffs, notably targeting Chinese imports. These measures aimed to reduce trade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback